Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens.
In patients with advanced uterine corpus carcinoma treated with the combination chemotherapy of megestrol, cyclophosphamide, and doxorubicin (MCA) or with this combination and 5-fluorouracil (MCAF), the overall response rate was 22%. There was no significant difference in response rates between the two regimens. There is some indication that survival was longer in ambulatory patients who were treated with MCA, but this combination produced more hematologic toxicity than MCAF. Patients unsuitable for treatment with doxorubicin received megestrol, 1-phenylalanine mustard, and 5-fluorouracil (MLF), which produced objective responses in 2 of 12 patients.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008535:Megestrol / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D008535:Megestrol; D008558:Melphalan; D005472:Fluorouracil